|
18 Nov 2020 |
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
|
|
18 Nov 2020 |
PureTech’s LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study
|
|
18 Nov 2020 |
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma
|
|
18 Nov 2020 |
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
|
|
18 Nov 2020 |
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
|
|
18 Nov 2020 |
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
|
|
18 Nov 2020 |
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100
|
|
17 Nov 2020 |
AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
|
|
17 Nov 2020 |
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
|
|
17 Nov 2020 |
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
|
|
17 Nov 2020 |
Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus
|
|
17 Nov 2020 |
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
|
|
17 Nov 2020 |
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
|
|
17 Nov 2020 |
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
|
|
17 Nov 2020 |
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
|
|
17 Nov 2020 |
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
|
|
17 Nov 2020 |
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
|
|
17 Nov 2020 |
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
|
|
17 Nov 2020 |
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development
|
|
17 Nov 2020 |
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
|
